EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae

Antonio Farina, Macarena Villagrán-García, Amna Abichou-Klich, Tifanie Alberto, Jérôme Aupy, Marie Benaiteau, Veronique Bourg, Giovanni Corazza, Aurélien Maureille, Géraldine Picard, Dimitri Psimaras, Marie Rafiq und 2 weitere

Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e015176

DOI: 10.1136/jitc-2026-015176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.06.2026. Verfasst von Antonio Farina und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Centre for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neurotoxicity Syndromes, Nervous System Diseases, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on the long-term course of neurological immune-related adverse events (n-irAEs) are limited by the size of studies as well as short and heterogeneous follow-up durations. Herein, we assessed the risk and predictors of 1-year neurological sequelae, and the frequency of n-irAE relapses with or without immune checkpoint inhibitor (ICI) rechallenge.

Methods

Patients with Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2 n-irAEs identified in a national reference center were included (2015–2024). Early neurological recovery was defined as CTCAE grade

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeurotoxicity SyndromesNervous System DiseasesNeoplasmsHumansMaleFemaleAgedMiddle Aged

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmune related adverse event - irAEImmunotherapyNeurotoxicityRelapse

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • National Reference Centre for Paraneoplastic Neurological Syndromes, Hospices Civils de Lyon, Lyon, France.
  • MeLiS-UCBL-CNRS UMR 5284, INSERM U1314, Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Biostatistics and Informatics Service, Hospices Civils de Lyon, Lyon, France.
  • Department of Neurology, Centre Hospitalier de Lille, Lille, France.
  • Department of Clinical Neurosciences, Centre Hospitalier de Bordeaux, Bordeaux, France.
  • Neurology, Côte d'Azur University Hospital, Nice, France.

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Farina, A., Villagrán-García, M., Abichou-Klich, A., Alberto, T., Aupy, J., Benaiteau, M., Bourg, V., Corazza, G., Maureille, A., Picard, G., Psimaras, D., Rafiq, M., Honnorat, J., & Joubert, B. (2026). Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae. Journal for ImmunoTherapy of Cancer, 14(6), e015176. https://doi.org/10.1136/jitc-2026-015176

Vancouver

Farina A, Villagrán-García M, Abichou-Klich A, Alberto T, Aupy J, Benaiteau M, et al. Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae. Journal for ImmunoTherapy of Cancer. 2026;14(6):e015176. doi:10.1136/jitc-2026-015176

BibTeX
@article{Farina2026,
  author = {Farina, Antonio and Villagrán-García, Macarena and Abichou-Klich, Amna and Alberto, Tifanie and Aupy, Jérôme and Benaiteau, Marie and Bourg, Veronique and Corazza, Giovanni and Maureille, Aurélien and Picard, Géraldine and Psimaras, Dimitri and Rafiq, Marie and Honnorat, Jerome and Joubert, Bastien},
  title = {Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {e015176},
  doi = {10.1136/jitc-2026-015176}
}
Kostenlos starten →